Tacrolimus Antibody Conjugated to ABEI

Tacrolimus Antibody Conjugated to ABEI

Tacrolimus Antibody Conjugated to ABEI is a chemiluminescent reagent designed for high-sensitivity detection of tacrolimus (FK506) in clinical and research settings. This product features a monoclonal antibody specific to tacrolimus, conjugated to ABEI (N-(4-Aminobutyl)-N-ethylisoluminol), a luminol derivative known for its stable and intense light emission. Supplied at 1 mg/mL in liquid format, this conjugate is optimized for use in CLIA platforms and therapeutic drug monitoring workflows.

Tacrolimus is a potent immunosuppressant used in organ transplantation and autoimmune disease management. The ABEI label enables sensitive detection in chemiluminescent immunoassays, allowing researchers and clinicians to quantify tacrolimus levels with precision and reproducibility. This reagent is particularly useful in pharmacokinetic studies, toxicity profiling, and assay development for transplant monitoring.

The antibody-ABEI conjugate offers high specificity, low background, and compatibility with manual and automated platforms. It is formulated in ultrapure water and filtered through 0.22 m membranes to ensure purity and consistency. Applications include CLIA assay development, tacrolimus pharmacology research, and biomarker discovery in dermatology, hepatology, and nephrology.

Key benefits:

• Monoclonal antibody conjugated to ABEI for chemiluminescent detection of tacrolimus
• Supports CLIA assay development and therapeutic drug monitoring
• High specificity and low background signal in complex matrices
• Biotechnology grade; filtered through 0.22 m membranes
• Supplied at 1 mg/mL; store at 20C to maintain activity

Products are for in vitro research use only (RUO).

References

• Ormerod AD. Cancer risk with topical tacrolimus and pimecrolimus. Br J Dermatol. 2005 Oct;153(4):701705.
• Peters DH et al. Pharmacology and therapeutic potential of tacrolimus. Drugs. 1993 Oct;46(4):746794.
• Spencer CM et al. Clinical efficacy of tacrolimus in transplantation. Drugs. 1997 Dec;54(6):925975.
• Haroon N et al. Tacrolimus toxicity with minimal symptoms. Am J Ther. 2016 MarApr;23(2):e631634.
• Truneka P. Once-daily tacrolimus in liver transplantation. Curr Opin Organ Transplant. 2017 Apr;22(2):118122.
• Posadas Salas MA et al. Clinical utility of once-daily tacrolimus. Drug Des Devel Ther. 2014 Sep 1;8:11831194.
• Pustisek N et al. Tacrolimus ointment for atopic dermatitis. Acta Dermatovenerol Croat. 2002 Mar;10(1):2532.
• Gewirtz AT, Sitaraman SV. Tacrolimus Fujisawa. Curr Opin Investig Drugs. 2002 Sep;3(9):13071311.
• Huppertz A et al. Food effects on tacrolimus formulations. Clin Pharmacol Drug Dev. 2021 Aug;10(8):899907.
• Rallis E et al. New roles for topical tacrolimus. Expert Opin Investig Drugs. 2007 Aug;16(8):12671276.